Primary Hepatic Neuroendocrine Carcinomas Treated with a Combination of Cisplatin and Etoposide as First-Line Chemotherapy: Two Case Reports Abstract #597

Introduction: Because primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare, a standard regimen has not yet been established. However, the combination of etoposide and cisplatin (EP) has been widely used to treat PHNEC.
Aim(s): We report two cases of PHNEC treated with EP and compare the efficacy of the EP regimen for PHNEC and pancreatic NEC (pNEC).
Materials and methods: We retrospectively analyzed the medical records of patients diagnosed with PHNEC and pNEC during January 2007–November 2012.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Shoichi Nakazuru

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2690 Marked Response to Nab-Paclitaxel in Advanced Neuroendocrine Carcinoma of Nasal Sinuses: A Case Report
Introduction: Sinonasal neuroendocrine carcinomas (SNECs) are a very rare and high-grade malignant epithelial neoplasm that is usually associated with a poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Zhirong Qi
Authors: Qi Z, Zhang Y, Li Y, Wang C, ...
#2699 Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)
Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Thomas Couronne
Authors: Couronne T, Fine C, Hadoux J, Lecomte T, ...
#2716 Neuroendocrine Carcinoma of the Upper Urinary Tract: A Case Report
Introduction: There are no dedicated guidelines for treatment of urothelial NEC given disease rarity. An aggressive approach, including neoadjuvant cisplatin-based chemotherapy + nephroureterectomy and adjuvant platinum-based chemotherapy, is recommended.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Roberta Elisa Rossi
#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling
Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Dr Julien Hadoux
#2835 Primary Hepatic Neuroendocrine Carcinoma: Case Report and Literature Review
Introduction: Primary hepatic neuroendocrine carcinoma (PHNEC) is an extremely rare neuroendocrine carcinoma (NEC) that originate from the liver. The diagnosis of PHNEC remains challenging because of its rarity, and its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Saidi M A, Ghomari S, ...